Project Description
Taufon
(solution 4% (eye drop)) Taufonum (guttae ophthalmicae)
international nonproprietary name
Taurine/Tauforine solution 4%.
Ref
BP-0141
Pharmacotherapeutic group
Preparation for eye pathology treatment. Preparation regulating metabolic processes.
Composition of the preparation
1 ml of preparation contains 40 mg of taurine.
Pharmacological action
Pharmacodynamics
Taufonisasulfur-containingamineacidthatformsintheorganismduringcysteinetransformationprocess. The preparation enhances energetic processes, stimulates reparation and regeneration processes on diseases of dystrophic nature and on diseases accompanied by an acute impairment of tissue metabolism. Being a sulfur-containing amine acid, the preparation contributes to the normalization of cell membrane function, improves energetic and metabolism processes, maintains the persistence of electrolytic composition of cell cytoplasm, inhibits the synaptic transmission (performs a neurotransmitter function).
It induces the normalization of eye tissue metabolism on diseases of dystrophic nature.
Pharmacokinetics
After instillation it is absorbed in microquantities. It is practically not subject to oxidation in the organism tissues. It is found in the free form in the liver, in the muscles, in heart, nerve and brain tissues, in the blood (in blood corpuscles more than in the plasma). Itisexcretedbythekidney.
Indications
The preparation is prescribed to adults on dystrophic retina diseases (comprising inherited retinal abiotrophy), cornea dystrophy, senile cataract, trauma cataract, irradiation cataract and other types of cataracts, as well as on cornea trauma (as a stimulator of reparation processes).
special indication
Not established
special warning
Not established
Dosage and method of administration
For cataracts taufon is prescribed in the form of instillation 1 – 2 drops 2—4 times a day during 3 months. The course is repeated with a month interval. On traumas the preparation is used in the same dose during one month.
For treatment of dystrophic diseases of retina and cornea penetrating wound, taufon is administered under the conjunctiva in the dose of 0,3 ml of 4% solution once a day during 10 days. The course shall be repeated in 6 – 8 months.
On glaucoma (open-angle) the preparation is used as eye drops (instillation) 2 times a day 20—30 before instillation of timolol.
overdosage
Cases of over dosing on using the taufon eye drops have not been specified.
safety measures
Not established
Side effects
Allergic reactions.
Contraindications
Higher sensitivity to taurine.
Interactions with other medicinal preparations
In patients with glaucoma (open-angle) it has been demonstrated a significant increase of hypotension action in case of combination with timolol. The enhancement of effect is achieved by increasing the outflow easiness rate and reducing the aqueous hydatoid production.
The form of release
Solution 4% (eye drops) in vials 5 ml.